This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.
Stroke, Volume 56, Issue Suppl_1 , Page A63-A63, February 1, 2025. Introduction:Stroke prevalence is highest in adults ages>65 years, the majority of whom are Medicare beneficiaries. Fee-for-Service (FFS) Medicare incentivizes utilization by paying for each service. One found higher LDL levels (81.5 mg/dL vs 78.9
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Stroke, Volume 56, Issue Suppl_1 , Page AWP235-AWP235, February 1, 2025. The odds ratio for good outcome in those with private insurance was significantly higher in comparison to Medicare (OR 1.47, 95% CI 1.06-2.03, Disparities in outcomes of patients with ischemic stroke have been associated with insurance coverage. 1.84, p=0.009).Conclusion:Amongst
tim.hodson Tue, 01/14/2025 - 11:19 Jan. tim.hodson Tue, 01/14/2025 - 11:19 Jan. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the SymplicitySpyral renal denervation (RDN) system, used in the Symplicity bloodpressure procedure.
tim.hodson Mon, 01/27/2025 - 09:47 Jan. tim.hodson Mon, 01/27/2025 - 09:47 Jan. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the SymplicitySpyral renal denervation (RDN) system, used in the Symplicity bloodpressure procedure.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content